GWAS of GLP1 medication efficacy We performed a GWAS of the percentage BMI loss phenotype ( n = 15,237), and identified a strong genome-wide significant association on chromosome (chr.) 6 (Fig
Patients can now choose treatment options beyond traditional liposuction
21 Vutrisiran, a small interfering RNA (siRNA) therapy that suppresses hepatic transthyretin production, demonstrated reductions in all-cause mortality and recurrent cardiovascular events in the HELIOS-B trial and received FDA approval for ATTR-CM in 2025
During your off weeks, mix in healthy whole foods to keep things interesting and your body guessing
Before prescribing semaglutide, clinicians should obtain a thorough medical history specifically addressing prior pancreatitis episodes, gallbladder disease, alcohol use, and family history of pancreatic disorders